Serious immune‐related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review

Shah, Mohsin; Jomaa, Mona K; Ferrarotto, Renata; Yeung, Sai Ching Jim; Hanna, Ehab Y.; Reyes‐Gibby, Cielito C.

doi:10.1002/hed.25911

Cited by 3 publications

(4 citation statements)

References 64 publications

(128 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13-AC significantly inhibited tumor growth. The mice were treated for 30 days and the average tumor volume in the control group was 519 ± 171 mm 3 , whereas the average tumor volume in the 13-AC-treated group was 241 ± 141 mm 3 ( Figure 6A). As compared with the control group, the tumor volume was significantly suppressed in the 13-AC groups by 53.56%.…”

Section: Antitumor Effect Of 13-ac On Human Oral Ca9-22 Cancer Cells mentioning

confidence: 99%

“…Clinicians use anti-epidermal growth factor receptor (EGFR) therapy and immune checkpoint inhibitors along with traditional cytotoxic chemotherapy in patients with recurrent or metastatic cancer [2]. However, immunotherapy-related adverse effects remain a critical issue [3], and the identification of reliable, predictive, and prognostic markers needs more validation by further clinical trials [4]. Poor prognosis is usually observed in patients with recurrent or metastatic disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

13-Acetoxysarcocrassolide Exhibits Cytotoxic Activity against Oral Cancer Cells through the Interruption of the Keap1/Nrf2/p62/SQSTM1 Pathway: The Need to Move Beyond Classical Concepts

et al. 2020

View full text Add to dashboard Cite

13-Acetoxysarcocrassolide (13-AC), a marine cytotoxic product isolated from the alcyonacean coral Lobophytum crassum, exhibited potent antitumor and immunostimulant effects as reported in previous studies. However, the 13-AC antitumor mechanism of action against oral cancer cells remains unclear. The activity of 13-AC against Ca9-22 cancer cells was determined using MTT assay, flow cytometric analysis, immunofluorescence, immunoprecipitation, Western blotting, and siRNA. 13-AC induced apoptosis in oral cancer cells Ca9-22 through the disruption of mitochondrial membrane potential (MMP) and the stimulation of reactive oxygen species (ROS) generation. It increased the expression of apoptosis- and DNA damage-related proteins in a concentration- and time-dependent manner. It exerted potent antitumor effect against oral cancer cells, as demonstrated by the in vivo xenograft animal model. It significantly reduced the tumor volume (55.29%) and tumor weight (90.33%). The pretreatment of Ca9-22 cells with N-acetylcysteine (NAC) inhibited ROS production resulting in the attenuation of the cytotoxic activity of 13-AC. The induction of the Keap1-Nrf2 pathway and the promotion of p62/SQSTM1 were observed in Ca9-22 cells treated with 13-AC. The knockdown of p62 expression by siRNA transfection significantly attenuated the effect of 13-AC on the inhibition of cell viability. Our results indicate that 13-AC exerted its cytotoxic activity through the promotion of ROS generation and the suppression of the antioxidant enzyme activity. The apoptotic effect of 13-AC was found to be mediated through the interruption of the Keap1/Nrf2/p62/SQSTM1 pathway, suggesting its potential future application as an anticancer agent.

show abstract

Section: Antitumor Effect Of 13-ac On Human Oral Ca9-22 Cancer Cells mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

13-Acetoxysarcocrassolide Exhibits Cytotoxic Activity against Oral Cancer Cells through the Interruption of the Keap1/Nrf2/p62/SQSTM1 Pathway: The Need to Move Beyond Classical Concepts

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To our knowledge, this is the first study to evaluate potential CVD‐irAEs in a large sample of HNC patients. In our previous systematic review, 25 we found only 11 published studies (6 case reports/series, 4 clinical trials, and 1 prospective study) on irAEs in HNC patients. We found from case reports/case series a total of eight patients with serious irAEs.…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors

Reyes‐Gibby,

Qdaisat,

Ferrarotto

et al. 2023

Head & Neck

Self Cite

View full text Add to dashboard Cite

BackgroundCardio‐oncology and emergency medicine are closely collaborative, as many cardiac events in cancer patients require evaluation and treatment in the emergency department (ED). Immune checkpoint inhibitors (ICIs) have become a common treatment for patients with head and neck cancer (HNC). However, the immune‐related adverse events (irAEs) from ICIs can be clinically significant.MethodsWe reviewed and analyzed cardiovascular diagnoses among HNC patients who received ICI during the period April 1, 2016–December 31, 2020 in a large tertiary cancer center. Demographics, clinical and cancer‐related data were abstracted, and billing databases were queried for cardiovascular disease (CVD)‐related diagnosis using International Classification of Disease‐version10 (ICD‐10) codes. We recorded receipt of care at the ED as one of the outcome variables.ResultsA total of 610 HNC patients with a median follow‐up time of 12.3 months (median, interquartile range = 5–30 months) comprised our study cohort. Overall, 25.7% of patients had pre‐existing CVD prior to ICI treatment. Of the remaining 453 patients without pre‐existing CVD, 31.5% (n = 143) had at least one CVD‐related diagnosis after ICI initiation. Tachyarrhythmias (91 new events) was the most frequent CVD‐related diagnosis after ICI. The time to diagnosis of myocarditis from initiation of ICI occurred the earliest (median 2.5 months, 1.5–6.8 months), followed by myocardial infarction (3.7, 0.5–9), cardiomyopathy (4.5, 1.6–7.3), and tachyarrhythmias (4.9, 1.2–11.4). Patients with myocarditis and tachyarrhythmias mainly presented to the ED for care.ConclusionThe use of ICI in HNC is still expanding and the spectrum of delayed manifestation of ICI‐induced cardiovascular toxicities is yet to be fully defined in HNC survivors.

show abstract

“…However, they can also cause a distinctive spectrum of side effects, influencing almost any organ. Shah et al (101), have conducted a systematic review analyzing databases on patients with HNC, treated with ICIs, who developed immune-related adverse events (irAEs). The authors have identified 46 treatment-related adverse events from the pooled 791 patients, with at least 12 having essential consequence to irAEs.…”

Section: Limitations Of the Currently Offered Antibody-based Approachesmentioning

confidence: 99%

Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies

Qaraghuli

2020

Front. Oncol.

View full text Add to dashboard Cite

Head and neck cancer (HNC) is a heterogeneous disease that includes a variety of tumors originating in the hypopharynx, oropharynx, lip, oral cavity, nasopharynx, or larynx. HNC is the sixth most common malignancy worldwide and affects thousands of people in terms of incidence and mortality. Various factors can trigger the development of the disease such as smoking, alcohol consumption, and repetitive viral infections. HNC is currently treated by single or multimodality approaches, which are based on surgery, radiotherapy, chemotherapy, and biotherapeutic antibodies. The latter approach will be the focus of this article. There are currently three approved antibodies against HNCs (cetuximab, nivolumab, and pembrolizumab), and 48 antibodies under development. The majority of these antibodies are of humanized (23 antibodies) or human (19 antibodies) origins, and subclass IgG1 represents a total of 32 antibodies. In addition, three antibody drug conjugates (ADCs: telisotuzumab-vedotin, indatuximab-ravtansine, and W0101) and two bispecific antibodies (GBR 1372 and ABL001) have been under development. Despite the remarkable success of antibodies in treating different tumors, success was limited in HNCs. This limitation is attributed to efficacy, resistance, and the appearance of various side effects. However, the efficacy of these antibodies could be enhanced through conjugation to gold nanoparticles (GNPs). These conjugates combine the high specificity of antibodies with unique spectral properties of GNPs to generate a treatment approach known as photothermal therapy. This approach can provide promising outcomes due to the ability of GNPs to convert light into heat, which can specifically destroy cancer cells and treat HNC in an effective manner.

show abstract

Serious immune‐related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review

Cited by 3 publications

References 64 publications

13-Acetoxysarcocrassolide Exhibits Cytotoxic Activity against Oral Cancer Cells through the Interruption of the Keap1/Nrf2/p62/SQSTM1 Pathway: The Need to Move Beyond Classical Concepts

13-Acetoxysarcocrassolide Exhibits Cytotoxic Activity against Oral Cancer Cells through the Interruption of the Keap1/Nrf2/p62/SQSTM1 Pathway: The Need to Move Beyond Classical Concepts

Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors

Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies

Contact Info

Product

Resources

About